10 minute read
Aug. 21, 2023

Ansofaxine: An Active Prodrug, Triple Reuptake Inhibitor for Major Depressive Disorder


oral serotonin-norepinephrine-dopamine reuptake inhibitor approved in China for major depressive disorder from serotinin-norepinephrine reuptake inhibitor, desvenlafaxine Transl. Psychiatry, May 10, 2023 Shandong Luye Pharmaceutical CO., CN

Drug Hunter Team

While SNRIs and selective serotonin reuptake inhibitors (SSRIs) have been hugely successful in treating major depressive disorder (MDD), many patients remain resistant to treatment or do not experience full symptom relief. The majority of current treatments for MDD increase levels of synaptic serotonin and/or norepinephrine by inhibiting their reuptake transporters SERT and NET, respectively.



Other molecules you may be interested in